Elli Papaemmanuil

Associate Professor Computational Oncology Service MSKCC, Isabl Co-founder & CEO

Elli Papaemmanuil is a distinguished scientist and entrepreneur who co-founded and currently serves as the CEO of Isabl, a company focused on transforming cancer diagnosis and treatment through genomic medicine.1 3

Academic and Professional Background

Elli Papaemmanuil holds a PhD in Human Population Genetics from the University of London, which she completed between 2004 and 2008.1 Her educational journey began with a Bachelor of Science in Human Molecular Genetics from the University of Glasgow from 2000 to 2004.1

Throughout her career, Dr. Papaemmanuil has held several notable positions:

Associate Professor of Computational Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) since 20152 5
Junior Team Leader at the University of Cambridge from 2016 to 20201
Senior Postdoctoral Research Fellow at Wellcome Trust Sanger Institute in 20101
Postdoctoral Researcher at The Institute of Cancer Research in 20041

Research and Expertise

Dr. Papaemmanuil is a molecular geneticist with expertise in:

Applying AI to precision medicine3
Systematic interrogations of clinical trial cohorts in leukemia and cancer2
Exploring how genetic and clonal architecture in patients' leukemias and tumors influence clinical outcomes2

Her research has been widely recognized, with publications in prestigious journals such as NEJM, Nature Genetics, and Nature Medicine. She has garnered over 43,000 citations and boasts an h-index of 70.3

Entrepreneurial Ventures

In 2020, Elli Papaemmanuil co-founded Isabl, where she serves as the CEO and Scientific Co-founder.1 3 Isabl aims to unlock the full potential of genomic medicine in cancer care by developing technology to profile tumor biopsies using whole genome and transcriptome sequencing within clinically relevant timeframes.3 6